fexofenadine and calcitriol

fexofenadine has been researched along with calcitriol in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Claro da Silva, T; Gubler, C; Ismair, MG; Jetter, A; Kullak-Ublick, GA; Spanaus, K1

Reviews

1 review(s) available for fexofenadine and calcitriol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for fexofenadine and calcitriol

ArticleYear
No major effects of vitamin D3 (1,25 dihydroxyvitamin D3) on absorption and pharmacokinetics of folic acid and fexofenadine in healthy volunteers.
    European journal of clinical pharmacology, 2016, Volume: 72, Issue:7

    Topics: Administration, Oral; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Duodenum; Female; Folic Acid; Healthy Volunteers; Humans; Intestinal Absorption; Male; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Proton-Coupled Folate Transporter; RNA, Messenger; Terfenadine; Vitamin D; Young Adult

2016

Other Studies

1 other study(ies) available for fexofenadine and calcitriol

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004